Aim: This study assessed the long-term safety, tolerability, and maintenance of the therapeutic effect of brexpiprazole in Japanese patients with schizophrenia.
S
CHIZOPHRENIA IS A chronic condition for which long-term treatment with antipsychotic medication is critical to prevent relapse and mitigate functional deterioration. 1, 2 Long-term safety is an important consideration when choosing an antipsychotic agent for the treatment of schizophrenia. This is especially relevant for benefit-risk assessments, since differences in efficacy among available antipsychotic agents appear to be smaller than difference in safety (weight gain, extrapyramidal symptoms [EPS] , prolactin increase, corrected QT interval prolongation, sedation, akathisia, and metabolic adverse effects). [3] [4] [5] These side-effects may worsen the patient's ability to function, diminish subjective well-being and quality of life, and contribute to poor treatment adherence. 6, 7 Brexpiprazole is approved in the USA, Canada, Australia, and Japan for the treatment of schizophrenia and in the USA as adjunctive treatment of major depressive disorder. It acts as a partial agonist at serotonin 5-HT 1A and dopamine D 2 receptors and as an antagonist at serotonin 5-HT 2A and noradrenaline α 1B/2C receptors, all with subnanomolar potency. 8 It has a lower intrinsic activity at the dopamine D 2 receptor and stronger antagonism at the serotonin 5-HT 2A receptor than aripiprazole, the first dopamine D 2 partial agonist approved for the treatment of schizophrenia. 8 Brexpiprazole had demonstrated efficacy, safety, and good tolerability in patients with schizophrenia in two randomized double-blind placebo-controlled 6-week phase-3 studies (ClinicalTrials.gov NCT01396421 [brexpiprazole 0.25, 2, or 4 mg, or placebo] and ClinicalTrials.gov NCT01393613 [brexpiprazole 1, 2, or 4 mg, or placebo]), 9, 10 and one randomized double-blind placebo-controlled 52-week maintenance study (ClinicalTrials.gov NCT01668797). 11 In addition, pooled safety data from two open-label, 52-week, long-term studies (ClinicalTrials.gov NCT01649557 and ClinicalTrials.gov NCT01397786) suggested that long-term treatment with brexpiprazole was well tolerated, with a favorable safety profile. 12 In one 6-week randomized double-blind placebo-controlled short-term study of brexpiprazole (1, 2, or 4 mg) in Japanese patients with schizophrenia, brexpiprazole had demonstrated efficacy and good tolerability (ClinicalTrials.gov NCT01451164). The aim of the current study was to evaluate the safety and effectiveness of brexpiprazole in the longer-term treatment of Japanese patients with schizophrenia.
METHODS
This study was conducted in compliance with the International Conference on Harmonisation good clinical practice consolidated guideline, and with local laws and regulatory requirements in Japan. The protocols were approved by the governing institutional review board for each investigational site. Written informed consent was obtained from all patients in the study.
Study design and patients
This was an open-label, multicenter, 52-week study conducted at 89 sites (Table S1) in Japan between October 2011 and June 2015 (ClinicalTrials.gov NCT01456897). This study enrolled two groups of schizophrenia patients: (i) rollover patients who completed the 6-week double-blind, randomized, placebo-controlled trial (ClinicalTrials.gov NCT01451164), or who discontinued the study after assessment at week 4 (for a reason other than withdrawal of consent) and satisfied the following criterion Clinical Global Impression-Improvement (CGI-I) score ≥ 5 (minimally worse) both at discontinuation and at the preceding scheduled visit; (ii) de novo patients who had not been enrolled in the short-term study. Eligible patients were: aged 18 years or older, had been diagnosed with schizophrenia based on DSM-IV-TR diagnostic criteria, were receiving treatment with oral antipsychotics (other than clozapine), required chronic antipsychotic treatment per the study investigator's opinion, and were considered for monotherapy with brexpiprazole. We excluded patients with: firstepisode schizophrenia, severe akathisia, clinically significant tardive dyskinesia, a DSM-IV-TR diagnostic criteria other than schizophrenia, a history of substance abuse or dependence within the past 180 days, or electroconvulsive treatment 60 days prior to informed consent. Patients who had complications or history of diabetes and had been judged by the investigators to be inappropriate for inclusion in this trial for any other reasons were also excluded.
All psychotropic agents, including antipsychotics (except during switching phase), antidepressants, mood stabilizers, and benzodiazepines (except for as short-term rescue therapy for the treatment of agitation and insomnia), ramelteon, suvorexant, nonbenzodiazepine sleep aids (except for limited treatment of insomnia), antihistamines (excluding medicine for treatment of a complication other than a psychiatric disorder and external application), beta blockers (except when used for the treatment of cardiovascular disease), varenicline, and supplements containing centrally acting substances (tryptophan and St. John's wort), were prohibited during the treatment period.
There were two consecutive treatment phases ( Fig. 1) : a 4-week switching phase (de novo patients switched from their prior antipsychotic therapy to brexpiprazole 2 mg/day using an add-on and taperoff method starting at a dose of 1 mg/day); and a 52-week open-label (OL) phase (patients were examined weekly for the first 2 weeks, biweekly for weeks 2-8, and every 4 weeks through week 52). In the OL phase, administration of brexpiprazole was started at a dose of 2 mg/day, and dose was to be subsequently increased by 1 mg at each scheduled visit based on the following dose-escalation criteria: if a CGI-I score was 3 (minimally improved) to 7 (very much worse) and if the investigator or subinvestigator judged that there was no problem with tolerability. It was permissible to reduce the dose at any time during the treatment period to a minimum of 1 mg/day for tolerability issues. However, the dose had to be reduced in 1-mg increments. Patients received brexpiprazole at a dose range of 1-4 mg/ day for 52 weeks. Post-treatment observation was also performed at 30 days after the final dose of brexpiprazole.
Assessments
Safety was assessed according to treatment-emergent adverse events (TEAE), clinical laboratory tests, vital signs, waist circumference, bodyweight, body mass index (BMI), 12-lead electrocardiogram (ECG), Drug-Induced Extrapyramidal Symptoms Scale (DIEPSS), Abnormal Involuntary Movement Scale (AIMS), Barnes Akathisia Rating Scale (BARS), and Columbia Suicide Severity Rating Scale. Efficacy was assessed according to the Positive and Negative Syndrome Scale (PANSS), the Clinical Global Impression-Severity (CGI-S), and the CGI-I.
Statistical analysis
The safety dataset for each phase included all patients who received ≥1 dose of brexpiprazole and had ≥1 post-baseline safety evaluation during the phase. The efficacy dataset included all patients who had ≥1 post-baseline efficacy evaluation. Baseline evaluations were performed prior to start of brexpiprazole administration in each phase. Endpoints were summarized using descriptive statistics for all patients and by groups (de novo or rollover). In each phase, safety was assessed by TEAE, including frequency, severity, seriousness, and discontinuation due to TEAE. In each phase, for safety quantitative test items, descriptive statistics of values at baseline and last observation and of the change from baseline were calculated. In the switching phase, descriptive statistics of values of the changes in PANSS total and CGI-S scores from switching phase baseline to week 4 were calculated using observed case (OC) data. In the OL phase, descriptive statistics of values of the changes in PANSS total, CGI-S, PANSS Positive subscale, PANSS Negative subscale, PANSS Excited Component, PANSS Marder Factor 13 scores from OL phase baseline to week 52 were calculated using OC and last-observation-carried-forward (LOCF) data. In the OL phase, descriptive statistics of values of CGI-I score at week 52 were determined using OC and LOCF data. In the OL phase, response rates at week 52 (defined as ≥30% reduction in PANSS total score from baseline of the OL phase or CGI-I score of 1 [very much improved] or 2 [much improved]) were calculated using OC and LOCF data. Rollover patients were enrolled from 6-week randomized doubleblind placebo-controlled trial with placebo or brexpiprazole at 1, 2, or 4 mg/day in Japanese patients with schizophrenia.
RESULTS

Patient disposition and characteristics
Patient disposition is shown in Figure 1 . De novo patients (n = 184) and rollover patients (n = 98) entered the OL phase, and 109 (59.2%) de novo patients and 41 (41.8%) rollover patients completed week-52 assessment. The most common reasons for discontinuation in the OL phase were withdrawal of consent and adverse events. Demographic and baseline clinical characteristics in the OL phase are shown in Table 1 .
Treatment exposure
In the switching phase, brexpiprazole was administered to 208 patients, and the duration of treatment was 4 weeks in most of these patients. The mean daily dose of brexpiprazole was 1.84 mg at the end of the switching phase.
In the OL phase, brexpiprazole was administered to 281 patients in total: 183 de novo patients and 98 rollover patients. The mean (SD) duration of treatment was 236.0 (148.0) days and the mean daily dose was 3.1 (0.8) mg in all patients. In the OL phase, concomitant use of benzodiazepines (lorazepam and diazepam) for agitation and insomnia aids, nonbenzodiazepine sleep aids, or anticholinergic antiparkinson drugs for treatment of EPS was reported in 69.1%, 9.2%, and 15.2% of all patients, respectively.
Safety Adverse events
In the switching phase, of the 208 patients who were included in the safety dataset, 97 (46.6%) experienced a TEAE. There were no deaths. Serious TEAE were reported in seven patients (3.4%) and the most frequently reported serious TEAE was worsening of schizophrenia (n = 5). Six patients (2.9%) discontinued the switching phase due to a TEAE and of these, four patients (1.9%) experienced worsening of schizophrenia.
A summary of TEAE during the OL phase is presented in Table 2 . Most cases were mild or moderate Values are expressed as mean (SD) unless specified otherwise. † Patients were switched from other antipsychotics to brexpiprazole 2 mg/day using an add-on and taper-off method within 4 weeks.
in severity. The most frequent TEAE were nasopharyngitis and worsening of schizophrenia. There were no deaths. Worsening of schizophrenia was the most frequently reported serious TEAE (n = 30, 10.7%) and it was the most frequently reported TEAE leading to discontinuation (n = 32, 11.4%). The discontinuation rate for akathisia was 1.1% (3/281). In this trial, 33 patients aged 65 years or older were administered brexpiprazole, and two of the patients experienced serious TEAE (one patient in each phase); both patients had worsening of schizophrenia, three patients discontinued due to TEAE (one in the switching phase and two in the OL phase; these patients had insomnia, thirst, and worsening of schizophrenia, respectively).
Other safety parameters
There was no clinically meaningful mean change from baseline in bodyweight during the switching phase. During the OL phase, the mean changes in bodyweight from baseline to end point (LOCF) and week 52 (OC) were 0.93 and 1.61 kg, respectively. During the OL phase, the incidence of clinically significant weight gain (≥7% increase from baseline) was 24.2% (68/281).
During the switching phase, the mean change from baseline in prolactin was decreased in both men and women. During the OL phase, the changes from baseline in prolactin were minor and not clinically meaningful in any patients (Table 3) .
Mean changes from baseline in fasting metabolic parameters during the OL phase were minor and not clinically meaningful (Table 3 ). There were no clinically meaningful mean changes from baseline in serum chemistry, hematology, urinalysis, insulin, vital signs (including blood pressure, heart rate, body temperature, BMI, and waist circumference), or ECG parameters during any of the phases. In addition, there were no clinically meaningful changes in DIEPSS, BARS, or AIMS scores.
In the switching phase, the occurrence of suicidal ideation was 1.4% (3/208) while no patients reported suicidal behavior, as recorded on the Columbia Suicide Severity Rating Scale. In the OL phase, the occurrence of suicidal ideation and behavior was 7.8% (22/281) and 0.4% (1/281), respectively. Suicidal ideation, self-injurious behavior, and intentional self-injury were reported as suicide-related TEAE, and the occurrences were 2.5% (7/281), 1.1% (3/281), and 0.7% (2/281), respectively. All cases were mild or moderate in severity.
Efficacy
In the switching phase, 201 patients were included in the efficacy dataset, and a total of 279 patients (182 de novo patients and 97 rollover patients) were included in the efficacy dataset in the OL phase. In the switching phase, the mean PANSS total and CGI-S scores were 69.62 and 3.43 at baseline and 67.17 and 3.35 at week 4 (OC), showing a change of −2.28 and −0.06, respectively. In the OL phase, the time course of mean PANSS total score using OC data is shown in Figure 2 . Mean PANSS total scores remained stable until week 52 in de novo and rollover patients. In the OL phase, mean changes in efficacy measures (PANSS total, PANSS Positive, PANSS Negative, PANSS Excited Component, CGI-S, PANSS Marder Positive, PANSS Marder Negative, PANSS Marder Disorganized Thought, PANSS Marder Uncontrolled Hostility/Excitement, and PANSS Marder Anxiety/Depression) from baseline to week 52 are shown in Table 4 . These efficacy parameters remained stable until week 52 in each group. Mean CGI-I scores at week 52 using OC and LOCF data in all patients were 3.13 and 3.61, respectively. The response rates at week 52 using OC and LOCF data in all patients were 28.0% (42/150) and 20.4% (57/279), respectively. In de novo patients, the mean changes from baseline in PANSS total score at week 52 using OC and LOCF data were −8.83 (n = 18) and −5.69 (n = 29) in patients aged 65 years or older and −6.65 (n = 91) and −2.62 (n = 153) in patients aged younger than 65 years, respectively.
DISCUSSION
This is the first long-term study of brexpiprazole for Japanese patients with schizophrenia. In this study, oral brexpiprazole was safe, well tolerated, and maintained long-term therapeutic effects. Most of the de novo patients who had been treated with prior antipsychotics were successfully switched to monotherapy with brexpiprazole within 4 weeks, and maintained long-term therapeutic effects with a tolerable safety profile. This suggests that brexpiprazole may provide a useful treatment option for patients with schizophrenia who are considering to switch their current antipsychotic medication due to safety or tolerability concerns. In patients aged 65 years or older, brexpiprazole was also safe and maintained long-term therapeutic effects. Therefore, brexpiprazole may provide a useful treatment option for older patients with schizophrenia; however, these results need to be interpreted with caution, as the number of patients aged over 65 years was low in this study. In this study, brexpiprazole showed a favorable safety profile without significant rates of adverse events that can be seen with existing antipsychotics (i.e., insomnia, tremor, akathisia, sedation, weight gain, corrected QT prolongation, or metabolic sideeffects). [3] [4] [5] 14, 15 In a 52-week open-label study comparing aripiprazole to olanzapine in patients with schizophrenia, insomnia was the most common adverse event reported in the aripiprazole and olanzapine groups (24% and 26%, respectively).
14 The incidence of insomnia in brexpiprazole treatment (6.0%) in our study was lower than that observed in aripiprazole treatment. In the 52-week open-label study of paliperidone in patients with schizophrenia, the most frequently reported EPS-related TEAE were tremor (13%) and akathisia (11%). 15 The incidences of tremor (4.3%) and akathisia (8.5%) in brexpiprazole treatment in our study were lower than those observed in paliperidone treatment. In addition, brexpiprazole showed no clinically meaningful mean changes in laboratory values, vital signs, or ECG parameters over a period of 52 weeks. The safety profile of brexpiprazole in this study was consistent with the safety profile seen in previous global long-term, open-label studies. 12 In addition, the therapeutic effect of brexpiprazole was maintained over 52 weeks. The favorable long-term tolerability and efficacy profile provides reason to anticipate that brexpiprazole will provide a valuable therapeutic option for treating Japanese patients with schizophrenia.
The limitation of the current study is lack of a placebo control group, which limits the ability to attribute outcomes to treatment with brexpiprazole.
In conclusion, brexpiprazole was generally safe and well tolerated and maintained therapeutic effects in the long-term treatment of Japanese patients with schizophrenia. Brexpiprazole will 
